End-To-End, How Do We Better Produce Gene Therapies?

End-To-End, How Do We Better Produce Gene Therapies?

Friday, January 19, 2024 12:30 PM to 1:30 PM · 1 hr. (US/Eastern)
Gene Therapy Manufacturing
Presentation
Theatre 2

Information

Chair

Nathalie Clement, Vice President, Vector Development, Translational Gene Therapies, Siren Biotechnology

12.30pm Presentation: Strategic Considerations for Viral Vector Platforms

Ian Goodwin, Director of Program Design and CMC Strategy for Advanced Therapies, FUJIFILM DIOSYNTH Biotechnologies

12.45pm Presentation: Manufacturing AAV Therapies for Ultra-Rare Disorders: The Perspective of a Small, Virtual Biotech Company

Chris Lorenz, Chief Technology Officer, Mahzi Therapeutics

1.00pm Presentation

George Buchman, Research Fellow, Catalent Cell & Gene Therapy


1.15pm Q&A

Modality
Gene Therapy
Fujifilm Diosynth Biotechnologies500FUJIFILM Diosynth Biotechnologies is an industry-leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting the biopharmaceutical industry in the development and production of biologics, vaccines and cell & gene therapies. Our focus is to combine technical leadership in process development and cGMP manufacturing supported by a strong team of over 4,000 employees and a reputation for excellent customer service. We are a trusted partner of many clients, from early stage biotechs to large pharma. Our locations: Watertown and Cambridge, MA Research Triangle Park, NC Holly Springs, NC, USA (coming in 2024) College Station, TX Hillerød, Denmark Teesside, UK Thousand Oaks, CA Key Service Areas: Cell Culture Services Microbial Fermentation Services Advanced Therapies Services Cell Therapy Gene Therapy Oncolytic Viruses Viral Vaccines Drug Product and Finished Goods Analytical Services CMC Support Services Process Characterization Process Validation Formulation Development Stability Testing Regulatory Services

Documents & Links

George BuchmanAAV End-To-End

Log in